​

TransMedics Group (TMDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TMDX Stock Forecast

TransMedics Group (TMDX) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $124.33, with a high of $142.00 and a low of $85.00. This represents a 100.40% increase from the last price of $62.04.

$50 $80 $110 $140 $170 $200 High: $142 Avg: $124.33 Low: $85 Last Closed Price: $62.04

TMDX Stock Rating

TransMedics Group stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (75.00%), 3 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 3 9 Strong Sell Sell Hold Buy Strong Buy

TMDX Price Target Upside V Benchmarks

TypeNameUpside
StockTransMedics Group100.40%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks38.52%

Price Target Trends

1M3M12M
# Anlaysts5614
Avg Price Target$122.20$123.50$137.50
Last Closing Price$62.04$62.04$62.04
Upside/Downside96.97%99.07%121.63%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 26272--11
Apr, 26272--11
Mar, 26273--12
Feb, 26273--12
Jan, 26273--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 06, 2026Needham$142.00$73.8492.31%128.88%
May 06, 2026William PlovanicCanaccord Genuity$124.00$94.9330.62%99.87%
May 06, 2026Piper Sandler$120.00$94.9326.41%93.42%
May 06, 2026Thomas StephanStifel Nicolaus$85.00$94.93-10.46%37.01%
May 06, 2026David RescottRobert W. Baird$140.00$94.9347.48%125.66%
Mar 09, 2026Stifel Nicolaus$130.00$134.77-3.54%109.54%
Dec 17, 2025Canaccord Genuity$148.00$125.0418.36%138.56%
Dec 08, 2025Needham$166.00$136.5121.60%167.57%
Dec 02, 2025Morgan Stanley$135.00$150.42-10.25%117.60%
Oct 30, 2025Matt O'BrienPiper Sandler$140.00$134.324.23%125.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 06, 2026Piper SandlerOverweightOverweighthold
May 06, 2026OppenheimerOutperformPerformdowngrade
Mar 16, 2026Cowen & Co.BuyBuyhold
Dec 22, 2025Piper SandlerOverweightOverweighthold
Dec 08, 2025NeedhamBuyBuyhold
Oct 30, 2025Piper SandlerOverweightOverweighthold
Oct 30, 2025Canaccord GenuityBuyBuyhold
Oct 30, 2025NeedhamBuyBuyhold
Oct 23, 2025NeedhamBuyBuyupgrade
Oct 13, 2025JefferiesBuyinitialise

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 $4 $5 $6 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.60$-1.23$-0.77$1.07$5.60---
Avg Forecast$-1.58$-1.33$-0.93$0.98$1.47$2.38$2.91$3.71
High Forecast$-1.46$-1.30$-0.90$1.05$1.70$2.72$2.95$3.76
Low Forecast$-1.69$-1.34$-0.96$0.91$1.17$1.72$2.84$3.62
Surprise %1.27%-7.52%-17.20%9.18%280.95%---

Revenue Forecast

$0 $190M $380M $570M $760M $950M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$30.26M$93.46M$241.62M$441.54M$605.49M---
Avg Forecast$28.29M$86.22M$228.47M$429.57M$524.07M$635.61M$787.30M$923.65M
High Forecast$29.87M$87.01M$230.40M$430.57M$529.01M$636.81M$798.35M$933.95M
Low Forecast$26.74M$84.84M$226.23M$428.45M$517.83M$634.40M$776.25M$906.76M
Surprise %6.98%8.39%5.76%2.79%15.54%---

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-44.22M$-36.23M$-25.03M$35.46M$190.29M---
Avg Forecast$-33.47M$-36.82M$-35.78M$32.64M$48.33M$84.88M$92.50M$120.48M
High Forecast$-26.78M$-29.46M$-28.62M$34.10M$55.13M$88.42M$96.00M$122.22M
Low Forecast$-40.17M$-44.18M$-42.93M$29.64M$38.09M$56.06M$92.38M$117.61M
Surprise %32.09%-1.60%-30.05%8.66%293.77%---

TMDX Forecast FAQ

Is TransMedics Group stock a buy?

TransMedics Group stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that TransMedics Group is a favorable investment for most analysts.

What is TransMedics Group's price target?

TransMedics Group's price target, set by 12 Wall Street analysts, averages $124.33 over the next 12 months. The price target range spans from $85 at the low end to $142 at the high end, suggesting a potential 100.40% change from the previous closing price of $62.04.

How does TransMedics Group stock forecast compare to its benchmarks?

TransMedics Group's stock forecast shows a 100.40% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (38.52%).

What is the breakdown of analyst ratings for TransMedics Group over the past three months?

  • May 2026: 18.18% Strong Buy, 63.64% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 18.18% Strong Buy, 63.64% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 16.67% Strong Buy, 58.33% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is TransMedics Group’s EPS forecast?

TransMedics Group's average annual EPS forecast for its fiscal year ending in December 2026 is $2.38, marking a -57.50% decrease from the reported $5.6 in 2025. Estimates for the following years are $2.91 in 2027, and $3.71 in 2028.

What is TransMedics Group’s revenue forecast?

TransMedics Group's average annual revenue forecast for its fiscal year ending in December 2026 is $635.61M, reflecting a 4.97% increase from the reported $605.49M in 2025. The forecast for 2027 is $787.3M, and $923.65M for 2028.

What is TransMedics Group’s net income forecast?

TransMedics Group's net income forecast for the fiscal year ending in December 2026 stands at $84.88M, representing a -55.40% decrease from the reported $190.29M in 2025. Projections indicate $92.5M in 2027, and $120.48M in 2028.